Redman has a stellar background!!!!
Michael T. Redman, CEO & Board Member
Mr. Redman is the chief executive officer of Oncolix, Inc. and has served in this position since formation of the company in November of 2006.
Prior to Oncolix, Mr. Redman was the CEO of Bone Medical, a public company focused in the area of oral peptide delivery of products related to musculoskeletal disorders. Immediately prior to Bone Medical, Mr. Redman was the CEO and co-founder of Opexa Pharmaceuticals, which commenced operations in February of 2001 and was successfully sold to PharmaFrontiers Corporation in November of 2004. PharmaFrontiers later reorganized the company, which is now named Opexa Therapeutics, a NASDAQ-listed company.
His career spans over 25 years in the pharmaceuticals and biotechnology industry and encompasses leadership in sales, marketing, business and commercial development. In addition to the three companies in which he served as CEO, Mr. Redman also held key management positions with Zonagen, Aronex Pharmaceuticals, Biovail, and American Home Products.
Mr. Redman has been instrumental in closing multiple pharmaceutical licensing deals, both domestic and international. These deals include in-licensing of university and NIH intellectual property, acquisitions and divestitures. He is an active member of the Licensing Executives Society and formerly served on its Executive Committee. Mr. Redman earned a BA in Biology from the University of Missouri and a Masters in Business Administration from the University of Phoenix.